

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Honliv Healthcare Management Group Company Limited

宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

QUARTERLY UPDATE ON STATUS OF RESUMPTION

This announcement is made by Honliv Healthcare Management Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to, among others, the announcements of the Company dated 19 March 2026, 25 March 2026, 21 April 2026, 18 May 2026, 18 June 2026 and 6 July 2026 (the “**Announcements**”) in relation to, inter alia, (i) suspension of trading; (ii) the resignation of PricewaterhouseCoopers (“**PwC**”) as auditor; (iii) the appointment of HLB Hodgson Impey Cheng Limited (“**HLB**”) as the new auditor; (iv) the delay in publication of the annual results for the year ended 31 December 2025 and the delay in despatch of the 2025 annual report of the Company; (v) the Resumption Guidance; and (vi) the quarterly update on status of resumption. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise specified.

QUARTERLY UPDATE ON THE RESUMPTION PROGRESS

The board of directors (the “**Board**”) would like to further update shareholders (the “**Shareholders**”) and potential investors of the Company on the latest developments with the Company’s business and progress with fulfilling the Resumption Guidance.

Resumption Plan

The Company has been working with its professional advisers to address the Resumption Guidance. The Company will seek to resume trading of the Shares on the Stock Exchange as soon as possible. Further announcement(s) will be made by the Company to update the Shareholders and the public on, among others, the resumption progress of the Company as and when appropriate.

Update on the Independent Investigation

The Company is pleased to announce that the Independent Forensic Investigator has completed the Independent Investigation, including the forensic work in relation to the bank loan and the transfer of the loan proceeds that was added to its scope following the Company's receipt of the Resumption Guidance.

The Independent Forensic Investigator is now preparing the Independent Investigation Report setting out its findings. Upon finalization of the Independent Investigation Report, the Company will publish further announcement(s) to inform the Shareholders of the key findings of the Independent Investigation.

Update on the Internal Control Review

The Company is pleased to announce that the Independent Internal Control Consultant has completed the Internal Control Review of, among other areas, the Company's policies and procedures in relation to: (i) corporate governance; (ii) monetary funds and payment; (iii) procurement and supplier management; (iv) financial accounting and reporting; and (v) related party transaction management.

The Independent Internal Control Consultant is now preparing the Internal Control Report. Upon finalization of the Internal Control Report, the Company will publish further announcement(s) to inform the Shareholders of the implementation progress of the recommended remedial actions and reinforcement measures.

Update on Publishing Outstanding Financial Information

As of the date of this announcement, HLB is still in the process of performing subsequent audit procedures as well as preparing and finalizing the 2025 Annual Results based on the observations and findings of the Independent Investigation and the Internal Control Review. The Company is actively cooperating with HLB to compile and provide the necessary information and documents as required by the auditor to complete the 2025 Annual Results. The Company will take all necessary steps to publish the 2025 Annual Results, the 2025 Annual Report, the 2026 Interim Results and the 2026 Interim Report, and despatch the 2025 Annual Report and the 2026 Interim Report as soon as possible.

The Board further announces that, in light of the delay in the publication of the outstanding financial information, the Company will publish a further announcement to inform the Shareholders of the date of the meeting of the Board to consider and approve the outstanding financial information as and when appropriate.

Update on Other Resumption Conditions

The Company will assess whether there is any regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations based on the findings of the Independent Investigation. Upon finalization of the Independent Investigation Report, the Company will make further assessment on this issue as and when appropriate.

The Company will continue to keep its Shareholders and potential investors abreast of any relevant material development by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules. The Company will continue to work closely with its professional advisers and proactively take all necessary and appropriate steps to comply with the Resumption Guidance, with the aim to resume trading in the Shares on the Stock Exchange as soon as practicable.

Business Operation

The Company is a healthcare services provider in the PRC. The Board confirms that the business operations and development of the Group remain as usual in all material respects and in the same manner as it has operated prior to the trading suspension.

The Group's principal operating subsidiary, Honliv Hospital, continues to operate and provide medical services to patients. The Board has continued to assess and monitor the impact (if any) of the suspension of trading in the Shares on the operations and financial performance of the Group. As at the date of this announcement, the Board is not aware of any material adverse impact of the trading suspension on the Group's business operations.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange was suspended with effect from 9:00 a.m. on 20 March 2026 and will continue to be suspended, pending the fulfilment of the Resumption Guidance and the grant of approval by the Stock Exchange for the resumption of trading in the Shares. For further details in relation to the Resumption Guidance, please refer to the announcement of the Company dated 18 May 2026.

Shareholders and potential investors of the Company should exercise caution when dealing in the Shares of the Company.

By order of the Board
Honliv Healthcare Management Group Company Limited
Mr. Qin Yan
Chairman

Hong Kong, 2 October 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Qin Yan, Mr. Wang Zhongtao and Ms. Li Yanhong as the executive Directors, Mr. Qin Hongchao as the non-executive Director and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive Directors.